Linden Thomas Advisory Services LLC Has $4.11 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Linden Thomas Advisory Services LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 44,531 shares of the biopharmaceutical company’s stock after purchasing an additional 1,630 shares during the quarter. Gilead Sciences comprises 0.5% of Linden Thomas Advisory Services LLC’s portfolio, making the stock its 28th biggest holding. Linden Thomas Advisory Services LLC’s holdings in Gilead Sciences were worth $4,113,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Avior Wealth Management LLC grew its position in Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after acquiring an additional 108 shares during the last quarter. Southland Equity Partners LLC boosted its stake in shares of Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 110 shares in the last quarter. Concord Asset Management LLC VA grew its holdings in shares of Gilead Sciences by 3.8% during the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 111 shares during the last quarter. TFB Advisors LLC raised its position in Gilead Sciences by 1.2% in the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock worth $788,000 after purchasing an additional 116 shares during the period. Finally, Sumitomo Life Insurance Co. lifted its stake in Gilead Sciences by 0.7% in the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock worth $1,494,000 after purchasing an additional 117 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock valued at $42,130,461 over the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

GILD opened at $93.07 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The stock has a fifty day simple moving average of $91.74 and a two-hundred day simple moving average of $84.86. The company has a market cap of $115.99 billion, a price-to-earnings ratio of 1,034.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.29 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Wall Street Analyst Weigh In

GILD has been the topic of several analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Wolfe Research started coverage on Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. UBS Group lifted their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Finally, Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target for the company. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.